SanBio Co ( (JP:4592) ) has provided an announcement.
SanBio Co., Ltd. announced the successful completion of their second commercial production run for AKUUGO Suspension, which is designed for intracranial implantation in regenerative medicine. The run met all required specifications, and the company plans to file a partial change application, maintaining their timeline for shipment in the second quarter of the fiscal year ending January 2026.
More about SanBio Co
SanBio Co., Ltd., founded in California in 2001, is a company operating in the regenerative medicine industry. They focus on the research, development, manufacturing, and sale of regenerative cell medicines, with a market emphasis on treatments for conditions such as chronic motor paralysis linked to traumatic brain injury.
YTD Price Performance: 0.0%
Average Trading Volume: 1,635
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $343.3M
Learn more about 4592 stock on TipRanks’ Stock Analysis page.